{
  "ticker": "LLY",
  "target_date": "2025-01-08",
  "actual_date": "2025-01-08",
  "collected_at": "2025-12-08T11:15:06.231944",
  "price": {
    "open": 768.1,
    "high": 786.69,
    "low": 764.96,
    "close": 781.3916625976562,
    "volume": 3478400,
    "change_1d_pct": 1.8,
    "change_7d_pct": 0.52,
    "change_30d_pct": 5.24
  },
  "technicals": {
    "rsi_14": 53.23,
    "sma_20": 774.99,
    "sma_50": 786.91,
    "macd": -5.992,
    "macd_signal": -7.132,
    "macd_histogram": 1.141,
    "bb_upper": 798.91,
    "bb_lower": 751.08,
    "price_vs_sma20_pct": 0.83,
    "price_vs_sma50_pct": -0.7,
    "volume_ratio": 1.09
  },
  "fundamentals": {
    "market_cap": 890602848256,
    "pe_ratio": 48.675648,
    "forward_pe": 43.842453,
    "price_to_book": 37.404743,
    "price_to_sales": 14.9883175,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.66,
    "pct_from_52w_low": 59.27
  },
  "macro": {
    "spy": {
      "price": 584.37,
      "change_1d_pct": 0.15,
      "change_7d_pct": 0.22
    },
    "vix": {
      "level": 17.7,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.69
    },
    "dollar_index": {
      "level": 109.09
    },
    "gold": {
      "price": 2664.5
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey",
      "source": "Yahoo",
      "datetime": 1736372698,
      "summary": "Companies have slowly been increasing coverage of GLP-1s for weight loss. Still, fewer than 50% do so.",
      "url": "https://finnhub.io/api/news?id=d4254328492e854aa93f2b4a16af1d2402a1ecc8b031e22a23e4dbd465e6ec38"
    },
    {
      "headline": "Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition",
      "source": "Yahoo",
      "datetime": 1736363771,
      "summary": "Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products",
      "url": "https://finnhub.io/api/news?id=0cd06e3e437361c100c87f0f45ea31ab4208267f0b27a266785ca1e1796f49ab"
    },
    {
      "headline": "Trump suggests Denmark tariff. How it could hit Novo Nordisk.",
      "source": "Yahoo",
      "datetime": 1736348796,
      "summary": "President-elect Donald Trump threatened higher tariffs against longtime ally Denmark over its ownership of Greenland as a Danish territory; Trump even floated the idea of the US purchasing Greenland. Denmark-based pharmaceutical company Novo Nordisk (NVO) is a major company that could be heavily imp",
      "url": "https://finnhub.io/api/news?id=e033ff82cae4ec024cf1c3f023f0638e461a957bcce8abccdf02d03cc866527e"
    },
    {
      "headline": "This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly",
      "source": "Yahoo",
      "datetime": 1736347500,
      "summary": "Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications.  One study suggests that it may even help reduce the risk of developing Alzheimer's.  There are many illnesses and con",
      "url": "https://finnhub.io/api/news?id=d5da7b765c713c8ac87ebb1efaeac6b1fde8bdf0a346704a1792d4c36710fbb6"
    },
    {
      "headline": "5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher",
      "source": "Yahoo",
      "datetime": 1736347500,
      "summary": "Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company\u2019s earnings and more.",
      "url": "https://finnhub.io/api/news?id=dc9f97067c224221aab0ea977c0112e8b570af743d83bc1d33c576dbb271ddad"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}